Objective-LL-37, the unique cathelicidin expressed in humans, in addition to acting as an endogenous antibiotic, is an important cell-signaling molecule upregulated in ovarian, breast, and lung tumors. However, the role of LL-37 in tumor microenvironment and its specific actions on the endothelial compartment remain elusive. Prostanoids are key regulators of inflammation, and cyclooxygenases (COXs) display proangiogenic activity in vitro and in vivo, mediated principally through prostaglandin E 2 (PGE 2 ). Here, we provide evidence for a novel proangiogenic role of LL-37, exerted via activation of endothelial cells and subsequent PGE 2 biosynthesis. Approach and Results-LL-37 triggers PGE 2 synthesis in endothelial cells in a dose-dependent manner with maximal induction after 4 hours. Endothelial PGE 2 biosynthesis was dependent on COX-1, rather than COX-2, as judged by pharmacological inhibition and gene silencing. In vitro matrigel assays supported these findings because LL-37-induced cord formation was abolished by COX-1, but not COX-2, small interfering RNA, and the angiogenic phenotype could be rescued by addition of exogenous PGE 2 . We find that LL-37 acts on endothelial cells as a potent calcium agonist, inducing phosphorylation and activation of cytosolic phospholipase A 2 (cPLA 2 ), promoting a cPLA 2 →COX-1→PGE 2 biosynthetic pathway and subsequent signaling via PGE 2 receptor EP3. Moreover, cathelicidin-related antimicrobial peptide, which is the murine ortholog of LL-37, induced prostaglandin-dependent angiogenesis in vivo, which could be blocked by aspirin. Conclusions-Our results identify a novel proangiogenic role of LL-37, suggesting that the axis LL-37/COX-1/PGE 2 followed by EP3 signaling is amenable to therapeutic intervention in pathological angiogenesis, for instance by aspirin. (Arterioscler Thromb Vasc Biol. 2013;33:1965-1972 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A ngiogenesis is a tightly regulated process that involves endothelial cell (EC) proliferation, migration, and tube differentiation. Persistent angiogenesis is a key feature of many pathological conditions in adults, such as tumor growth and metastasis, diabetic retinopathy, and chronic inflammatory disorders. 1 Previous studies indicate that the enzymes involved in arachidonic acid (AA) metabolism and their products play a potential role in tumor-induced angiogenesis. 2 Targeted inhibition of cyclooxygenases (COX-1 and COX-2), rate-limiting enzymes in prostanoid biosynthesis, by both traditional nonsteroidal anti-inflammatory drugs (nonselective COX inhibitors) and COXIBs (COX-2 selective nonsteroidal anti-inflammatory drugs) inhibit tumor angiogenesis and growth. [3] [4] [5] COX-2 and its downstream product PGE 2 have been shown to promote tumor angiogenesis and represent a novel angiogenic switch in breast cancer progression. 6 In fact, COX-2 expression is elevated in transformed cell lines and tumor tissues, and genetic inactivation of COX-2 or the PGE 2 receptor EP2 results in reduced vascular density and, therefore, in smaller intestinal polyps in Apc mutant mice, a model of human familial adenomatous polyposis. 7 Whereas the role of COX-2 in tumor-associated angiogenesis has been studied in depth, it is not clear which is the actual contribution of COX-1, 2 although some findings indicate that COX-1 might play a role in intestinal polyposis and ovarian cancer. 2, 3 Four G-protein-coupled receptors for PGE 2 denoted EP1, EP2, EP3, and EP4 have been cloned and characterized. 8 These receptors trigger diverse intracellular signaling pathways and bioactivities, depending on the type of associated G-protein. Because angiogenesis is regulated by EP receptor signaling, selective EP antagonists have emerged as an attractive approach to block angiogenesis downstream of COX activity. 2 Recent evidence indicates that LL-37/hCAP-18 is a multifunctional polypeptide that exerts a central role in innate immunity by linking host defense and inflammation. 9 In addition to its microbicidal activity, LL-37 transactivates the epidermal growth factor receptor inducing cytokine release and cell migration 10, 11 and stimulates chemotaxis and angiogenesis through the G-protein-coupled receptor, FPR2. [12] [13] [14] Furthermore, hCAP18/LL-37 is actively involved in tissue repair and wound healing 15 processes that share fundamental features with tumor growth and progression. Histological examination of ovarian, 16 breast, 17 and lung tumors 18 has shown that LL-37 is upregulated in these malignancies. LL-37 further promotes recruitment and engraftment of multipotent mesenchymal stromal cells into tumors. 16 However, the role of LL-37 in tumor microenvironment and its specific actions on the endothelial compartment, an essential player in the angiogenic process, remain elusive.
Here, we investigate the angiogenic role of LL-37 in human primary ECs. Our findings indicate that LL-37 elicits angiogenic responses via COX-1-derived PGE 2 , which triggers EP3 signaling. These results provide new insights to the molecular basis of LL-37 proangiogenic properties that could help develop novel antiangiogenic therapies.
Results

LL-37 Induces PGE 2 Biosynthesis in ECs
LL-37 stimulation triggers PGE 2 synthesis by EC in a dosedependent manner with a maximal induction at 60 µg/mL of peptide ( Figure 1A ). At this LL-37 concentration, the PGE 2 production reached its plateau after 4 hours of stimulation ( Figure 1B) . At 60 µg/mL, we did not detect any cytotoxic effects of LL-37 on human umbilical vein endothelial cells (HUVECs), as assessed by Trypan blue exclusion. On the contrary, this dose induced a moderate, but statistically significant, increase of cell viability after 4 and 8 hours of treatment ( Figure 1C ). Biosynthesis of prostacyclin and thromboxane was also modestly increased by LL-37 but only at the highest concentration (60 µg/mL) and after 8 and 24 hours, respectively ( Figure I in the online-only Data Supplement).
LL-37 Induces Intracellular Ca 2+ Mobilization and Phosphorylation of cPLA 2 in ECs
Traditionally, cPLA 2 has been considered a rate-limiting step during prostaglandin formation. 19 However, in HUVECs, total cPLA 2 expression was unaffected by LL-37 treatment ( Figure 2B ; Figure II in the online-only Data Supplement). To address whether LL-37 could promote PGE 2 biosynthesis Figure 1 . LL-37 triggers prostaglandin E 2 (PGE 2 ) biosynthesis by human umbilical vein endothelial cells (HUVECs). Cells were challenged with different concentrations of LL-37 for 6 hours (A) or with LL-37 (60 µg/mL) for various times (B and C). PGE 2 levels were measured by enzyme immunoassay (EIA). LL-37 triggers Ca 2+ mobilization by human umbilical vein endothelial cells (HUVECs) and phosphorylation of cytosolic phospholipase A2 (cPLA 2 ). A, Cells were challenged with LL-37 (60 µg/mL) at various time points, and intracellular Ca 2+ mobilization was monitored. Control wells containing cells that have not been exposed to FURA-2 AM were used to substract background autofluorescence. Data expressed as relative mean fluorescence intensity represent mean±SD. B, Western blot showing concomitant inductions of phospho-cPLA 2 and phospho-ERK-1/2 in lysates of HUVECs treated with LL-37 (60 µg/mL) and constitutive total cPLA 2 . Results shown are representative of ≥3 independent experiments. α-tubulin was used as loading control. C, Graphic shows cPLA 2 activity in lysates of endothelial cells disrupted after LL-37 treatment. cPLA 2 activity, expressed in nmol/min per milliliter, is mean±SD of 3 independent experiments. *P<0.05 vs untreated (Student t test).
via enzymatic activation of cPLA 2 , we analyzed intracellular calcium mobilization and mitogen-activated protein kinases phosphorylation in LL-37-activated HUVECs. LL-37 (60 µg/ mL) induced substantial intracellular Ca 2+ mobilization in ECs ( Figure 2A ) and concomitant enhancement of cPLA 2 activity ( Figure 2C ), which correlated with detection of cPLA 2 and Erk phosphorylation by Western blot analysis ( Figure 2B ). Further support for the involvement of Erk was provided by experiments where HUVECs were pretreated with PD98059 (MEK1,2 selective pharmacological inhibitor), which completely abolished the LL-37-induced PGE 2 formation ( Figure  III in the online-only Data Supplement).
COX-1 Is the Major Enzyme Contributing to LL-37-Derived PGE 2
In heterologous systems, such as HUVECs, COX-1 and COX-2 are coexpressed and could both participate in the LL-37-induced PGE 2 biosynthesis ( Figure II in the onlineonly Data Supplement). To elucidate the specific contribution of each COX isoenzyme, we measured endothelial PGE 2 production in the presence of a selective COX-2 inhibitor (Etoricoxib) versus a nonselective COX inhibitor (acetylsalicylic acid [ASA]). PGE 2 production was essentially abolished in the presence of ASA, whereas Etoricoxib only partially diminished PGE 2 biosynthesis in resting and stimulated cells ( Figure 3A ). The selectivity of COX inhibitors has been questioned 2, 19 ; therefore, we knocked down the expression of COX isoenzymes with specific small interfering RNAs. COX-1 or COX-2 protein was effectively and specifically suppressed and knockdown of one did not alter the expression of the other ( Figure IV in the online-only Data Supplement). COX-2 silencing corroborated the results obtained with Etoricoxib, showing only a minor contribution of this isoenzyme to LL-37-induced PGE 2 biosynthesis. In contrast, COX-1 silencing caused a dramatic decrease in PGE 2 levels ( Figure 3B ).
COX-1 Activity and PGE 2 Are Involved in LL-37-Induced Angiogenesis
To study the possible participation of endothelial PGE 2 in LL-37-mediated angiogenesis, we performed in vitro Matrigel experiments. LL-37 treatment induced endothelial cord formation by HUVECs, with a similar potency as classical proangiogenic factors, such as vascular endothelial growth factor ( Figure 4A ). Next, we evaluated the effect of COX inhibitors on the ability of LL-37-activated HUVECs to form capillary-like structures when seeded on Matrigel. As depicted in Figure 4B , ASA (nonselective COX inhibitor) impairs the LL-37-induced cord formation by HUVECs, whereas Etoricoxib (COX-2 selective inhibitor) did not significantly affect the ability of HUVECs to produce cords. Furthermore, ASA suppression of endothelial cord formation could be fully restored by addition of exogenous PGE 2 . In contrast, addition of exogenous PGE 2 did not modify the cord area in LL-37stimulated HUVECs pretreated with Etoricoxib.
To further corroborate these findings, we performed Matrigel assay with HUVECs transfected with small interfering RNA for each COX ( Figure 4C ). Knockdown of endothelial COX-1 dramatically reduced the cord formation on LL-37 stimulation. In contrast, COX-2 silencing did not significantly alter cord formation compared with control HUVECs transfected with scrambled small interfering RNA. Furthermore, the decreased and disorganized cord-like structures produced by LL-37-challenged ECs, in which COX-1 has been silenced, could be fully restored on addition of exogenous PGE 2 ( Figure V in the online-only Data Supplement), indicating that COX-1-derived PGE 2 accounts for LL-37 proangiogenic activities in EC.
PGE 2 -EP3 Signaling Is Involved in LL-37-Induced Angiogenesis
Angiogenesis is regulated by EP receptors, thus making selective EP antagonists an attractive approach to block angiogenesis downstream of COX activity. 2 To decipher which EP receptor(s) are involved in LL-37triggered PGE 2 proangiogenic signaling, we performed in vitro matrigel assays in presence of selective antagonists of EP1, EP3, and EP4 (to date, there are no EP2 selective antagonists available). 8 As shown in Figure 5 , the ability of LL-37-activated HUVECs to form capillary-like structures when seeded on Matrigel was moderately affected by AH6809 (EP1, EP2, EP3 antagonist) and L161,982 (EP4 antagonist). Of note, only the EP3 selective antagonist L798,106 caused a significant reduction of LL-37-induced cord formation, suggesting that EP3 is the major EP receptor involved in LL-37-induced angiogenesis in vitro. Similar results were obtained with the Matrigel assay when HUVECs were exposed to PGE 2 in the presence or absence of the EP3 antagonist ( Figure VI in the online-only Data Supplement).
LL-37-Induced Angiogenesis In Vivo Requires COX Activity
To substantiate the in vitro findings on the mechanism of LL-37-mediated angiogenesis, we performed a directed in vivo angiogenesis assay (DIVAA). For these experiments, we used murine cathelin-related antimicrobial peptide (mCRAMP), the murine ortholog of LL-37.
As depicted in Figure 6A , mCRAMP elicited prominent vascular growth with multiple, branched capillaries invading the angioreactor. By contrast, mCRAMP-induced vascularization of the angioreactor was virtually abolished in the presence of ASA, and these samples showed similar vascularization levels as the negative control (PBS).
Consistently with these observations, the mean relative fluorescence intensity of EC isolated from the mCRAMPtreated angioreactors was ≈10-fold higher than that observed for the control PBS angioreactors ( Figure 6B ). In addition, the relative fluorescence values of the cells from the ASA-mCRAMP-treated angioreactors were drastically reduced as compared with mCRAMP-treated angioreactors and were not statistically different from those values corresponding to the negative control (PBS-treated angioreactors).
These data show that mCRAMP (murine ortholog of LL-37) induces angiogenesis in vivo, which is mediated through prostaglandin biosynthesis because ASA (COX inhibitor) completely abrogated mCRAMP-induced angiogenesis, thus corroborating our in vitro results on LL-37-induced prostaglandin-dependent angiogenesis.
Similar results were obtained when angioreactors were treated with heterologs of LL-37, although the vascularization was less pronounced ( Figure VII in the online-only Data Supplement).
Discussion
Emerging evidence suggests that LL-37, in addition to acting as an endogenous antibiotic, is an important cell-signaling molecule that stimulates the recruitment of circulating immune effector cells 9 and the migration of keratinocytes and epithelial cells in vitro. 10, 11 Furthermore, LL-37 has been found in breast and ovarian carcinomas, 16, 17 and acts as a growth factor for lung cancer cells. 18 Tumor-associated angiogenesis is required to sustain tumor cell function and survival. 1 Hence, LL-37 has been described as an inducer of angiogenesis by a direct action on EC. 13 However, the mechanisms underlying the proangiogenic activities of LL-37 on EC have not been elucidated. 
LL-37 Triggers Proangiogenic PGE 2 Biosynthesis in ECs
In the past several years, prostanoids have emerged as key regulators of tumor-induced angiogenesis. 2 Targeted COX inhibition in tumor, stromal, and ECs is an attractive antiangiogenic strategy. 2 HUVECs release detectable amounts of prostanoids (PGE 2 , prostacyclin, thromboxane) under resting conditions. LL-37 stimulation increased significantly the levels of PGE 2 , and to a minor degree prostacyclin and thromboxane in the cell supernatants (Figure 1; Figure I in the onlineonly Data Supplement). LL-37 triggered PGE 2 biosynthesis in EC in a dose-dependent manner with a maximal induction after 4 hours of peptide stimulation ( Figure 1A and 1B) . Considering the significant increase in PGE 2 levels and the fact that this prostanoid is strongly implicated in the context of tumor progression and angiogenesis 2, 6 ; we focused our studies on the potential role of LL-37 for PGE 2 -dependent angiogenesis in ECs.
In the present study, the concentration of LL-37 inducing maximal PGE 2 release was 60 μg/mL (≈12 μmol/L), which is in the range previously used in studies related to ECs. 20 Although LL-37 has been claimed to exert cytotoxic effects on eukaryotic cells at high concentrations, 21 we could not observe any detrimental effect of 60 μg/mL of LL-37 on EC viability ( Figure 1C ). In fact, the LL-37 cytotoxic effects against eukaryotic cells seem to be highly dependent on the cell type, which has been associated with the ability of the peptide to differentiate between membranes with different composition. 21 Furthermore, it has been suggested that LL-37 alone activates cell-signaling pathways only at high concentrations, 10 which in vivo could occur at sites of acute inflammation, particularly at the leukocyte-endothelium interphase where LL-37 can be released from neutrophils and the precursor hCAP-18, which is abundant in plasma, 22 or in the tumor microenvironment. [16] [17] [18] 
LL-37-Induced PGE 2 -Dependent Angiogenesis Seems Not to Involve FPR2
Earlier studies have indicated a role of LL-37 in angiogenesis 13 and reendothelization, 14 which was dependent on FPR2 signaling. Although we could detect a functional FPR2 in ECs ( Figure VIII in the online-only Data Supplement), we did not observe any significant contribution of FPR2 signaling to LL-37-triggered PGE 2 biosynthesis. Neither a selective FPR2 antagonist (WRW4) nor a general inhibitor of Gi protein-coupled receptors (pertussis toxin) affected LL-37induced PGE 2 levels in HUVECs ( Figure IX in the onlineonly Data Supplement). Instead we could observe how LL-37 is internalized by ECs following an endocytic pathway, which seems to be a prerequisite for LL-37-induced PGE 2 release (Figures X and XI in the online-only Data Supplement).
Although the immunomodulatory properties of LL-37 have been widely studied, its mechanisms of interaction with eukaryotic cells are poorly understood. Hence, further studies are warranted to investigate the mode of interaction between LL-37 and ECs.
cPLA 2 /COX-1/PGE 2 /EP3 Signaling Mediates LL-37-Induced Angiogenesis
Our results indicate that LL-37 triggers PGE 2 biosynthesis via a COX-1-dependent mechanism. Previous studies have attributed PGE 2 -dependent tumor angiogenesis to COX-2 expression in ECs. 2, 19 Our findings, however, support an important contribution of COX-1 in ECs. COX-1 pharmacological inhibition (ASA) or silencing abrogated LL-37-induced production of PGE 2 , whereas COX-2 selective inhibition (Etoricoxib) or knockdown did not significantly affect LL-37-induced PGE 2 release (Figure 3) . These data corresponded well with angiogenesis matrigel assays, which showed that LL-37induced cord formation by ECs was significantly reduced by COX-1 knockdown or pharmacological inhibition with ASA ( Figure 4) . Moreover, the LL-37-mediated angiogenic phenotype was further restored by addition of exogenous PGE 2 . On the contrary, COX-2 knockdown or selective inhibition (Etoricoxib) did not significantly alter the ability of LL-37 to induce cord formation, further corroborating a role for the LL-37-COX-1-PGE 2 signaling pathway in ECs.
Although we could observe a modest upregulation of COX-2 protein expression in ECs on LL-37 stimulation ( Figure II in the online-only Data Supplement), we were unable to demonstrate any significant contribution of COX-2 to LL-37-mediated PGE 2 biosynthesis (Figure 3) . In contrast, the mild upregulation of prostacyclin and thromboxane levels observed at the highest concentration of peptide at late time points was sensitive to Etoricoxib, suggesting a COX-2 dependence (Figures I and XII in the online-only Data Supplement).
COX-1 expression remained unaltered ( Figure II in the online-only Data Supplement), as previously observed in other cell types with other stimuli, including ECs. 19 Hence, COX-1 could act as a constitutive producer of proangiogenic PGE 2 at early stages of tumorigenesis, before COX-2 induction, as supported by recent findings of aspirin chemopreventive effects at low, antiplatelet doses. 23 In addition, COX-1 could also cooperate with COX-2 in the production of prostanoids at more advanced stages of tumorigenesis. 3 Uncertainty about the role of COX-1 in angiogenesis has been suggested to reflect the lack of appropriate tools to specifically delineate the contribution of COX-1 and COX-2 to this process. 2, 3, 19 Studies in cells expressing both COX-1 and COX-2 demonstrated that both enzymes may contribute to prostanoid biosynthesis, although substrate availability can regulate their catalytic activity with striking differences observed between COX isoenzymes. 19 Thus, COX-1, but not COX-2, exhibits negative allostery at low AA concentrations; supporting the concept that COX-1 requires larger amounts of substrate, although COX-2 is very efficient at low concentrations of AA.
Based on these considerations, we also studied the effect of LL-37 on the availability of AA released from cellular phospholipids via cPLA 2 in ECs. In line with previous findings on other cell types, 24 LL-37 modulates the intracellular calcium flux, which is a key activator of cPLA 2 and AA release (Figure 2A ). LL-37 further activates cPLA 2 by inducing its phosphorylation in an Erk-dependent manner ( Figure 2B ). The enhanced endothelial cPLA 2 activity might result in considerable AA release, thus feeding a COX-1 activity that requires high concentrations of substrate ( Figure 2C) .
Our results indicate that LL-37 triggered PGE 2 signals via EP3 receptor to induce angiogenesis ( Figure 5 ). These findings are in line with previous studies showing that PGE 2 -EP3 receptor signaling in host stroma is critical for angiogenesis and tumor growth. 25 EP3 receptor signaling mediates upregulation of matrix metalloproteinase 9 expression 26 and activates the fibroblast growth factor receptor type 1 pathway in microvascular ECs. 27 Notably, we also observed a minor effect of EP1 and EP4 receptor antagonists on LL-37-induced PGE 2 -dependent angiogenesis ( Figure 5B ). Hence, we cannot exclude that these 2 receptors may contribute to the overall proangiogenic response. However, the biological outcome will depend on several factors, such as the ligand affinity for the receptor (10fold higher for EP3 and EP4 than for EP1) or the different sensitivities to agonist-induced desensitization (EP4 is more rapidly internalized and desensitized), 2 which could favor the PGE 2 -EP3 signaling observed in HUVECs.
In fact, control matrigel experiments, where HUVECs were incubated in the presence of EP selective antagonists with exogenous PGE 2 , to avoid any limiting effects by PGE 2 levels gave similar results ( Figure VI in the online-only Data Supplement).
Selective targeting of downstream effectors of the COX pathway, such as EP receptors, is a promising antiangiogenic approach, with the potential to avoid cardiovascular and gastrointestinal side effects derived from COX inhibition. 2 Our data suggest that a highly selective EP3 antagonist could exhibit chemopreventive actions targeting the endothelial compartment, and may become a novel therapeutic tool for cancer or other angiogenic-related pathologies.
LL-37 Induces Prostaglandin-Dependent Angiogenesis In Vivo, Inhibition by ASA
To further substantiate our mechanistic data on LL-37induced, PGE 2 -dependent angiogenesis in ECs, we moved to an in vivo angiogenesis model in the mouse. We found that mCRAMP (LL-37 murine ortholog), and to a lesser extent LL-37 itself ( Figure VII in the online-only Data Supplement), induces neovascularization in the DIVAA (Figure 6 ). In this model, we could observe the local-regional effects of LL-37/ mCRAMP on the coordination of host EC functions (proliferation, migration, and invasion), leading to the formation of new blood vessels in the angioreactor.
Our results are in line with a previous study by Koczulla et al 13 in which the authors demonstrated that mice with a global deficiency in mCRAMP exhibit decreased wound healing. This finding was interpreted as a result of impaired angiogenesis, although migratory keratinocytes/epithelial cells may well have played a role in the healing response and are known to be major targets of LL-37/mCRAMP. 15, 28 Our DIVAA model allows specific assessment of mCRAMPinduced angiogenesis and fluorimetrical quantification of the resulting neovascularization by invading host EC, thus unambiguously demonstrating the proangiogenic effects of the peptide.
In addition, our study shows a clear involvement of COX activity and prostaglandins in the endothelial angiogenetic response induced by mCRAMP because ASA-treated angioreactors showed a dramatic decrease in host EC invasion.
In conclusion, we have demonstrated that LL-37 can stimulate a proangiogenic response in human EC via biosynthesis and release of PGE 2 in a COX-1-dependent manner followed by EP3 receptor signaling ( Figure XIII in the online-only Data Supplement). Inasmuch as LL-37 has been associated with tumorigenesis, 29 our findings point to an LL-37-dependent proangiogenic pathway that holds promise for therapeutic intervention in neoplastic disorders. Moreover, our data offer a potential mechanism for the beneficial effects of low-dose aspirin when used as an antitumorigenic agent. 
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